117 related articles for article (PubMed ID: 7783344)
1. [Prospects for antisense therapy].
Maekawa T
Rinsho Ketsueki; 1995 May; 36(5):410-8. PubMed ID: 7783344
[TBL] [Abstract][Full Text] [Related]
2. [Prospects for antisense therapy of human leukemias].
Maekawa T
Hum Cell; 1996 Mar; 9(1):17-24. PubMed ID: 9183625
[TBL] [Abstract][Full Text] [Related]
3. Antisense approaches to cancer gene therapy.
Mercola D; Cohen JS
Cancer Gene Ther; 1995 Mar; 2(1):47-59. PubMed ID: 7621254
[TBL] [Abstract][Full Text] [Related]
4. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
5. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
6. Antisense strategy in hematological malignancies.
Warzocha K
Cytokines Cell Mol Ther; 1999 Mar; 5(1):15-23. PubMed ID: 10390076
[TBL] [Abstract][Full Text] [Related]
7. Antisense therapy for cancer.
Gleave ME; Monia BP
Nat Rev Cancer; 2005 Jun; 5(6):468-79. PubMed ID: 15905854
[TBL] [Abstract][Full Text] [Related]
8. Antisense therapy in malignant diseases: status quo and quo vadis?
Tamm I
Clin Sci (Lond); 2006 Apr; 110(4):427-42. PubMed ID: 16526947
[TBL] [Abstract][Full Text] [Related]
9. Antisense oligodeoxynucleotide therapy targeting clusterin gene for prostate cancer: Vancouver experience from discovery to clinic.
Miyake H; Hara I; Gleave ME
Int J Urol; 2005 Sep; 12(9):785-94. PubMed ID: 16201973
[TBL] [Abstract][Full Text] [Related]
10. [Development of antituberculous drugs: current status and future prospects].
Tomioka H; Namba K
Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
[TBL] [Abstract][Full Text] [Related]
11. [Basics of antisense oligonucleotide therapy and current therapeutical strategies in urology].
Kausch I; Böhle A
Aktuelle Urol; 2003 Dec; 34(7):458-68. PubMed ID: 14655082
[TBL] [Abstract][Full Text] [Related]
12. Applications of antisense oligonucleotides in oncology.
Pierga JY; Magdelenat H
Cell Mol Biol (Noisy-le-grand); 1994 May; 40(3):237-61. PubMed ID: 7920172
[TBL] [Abstract][Full Text] [Related]
13. Not nonsense but antisense--applications of antisense oligonucleotides in different fields of medicine.
Oberbauer R
Wien Klin Wochenschr; 1997 Jan; 109(2):40-6. PubMed ID: 9123943
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of hepadnaviral replication by polyethylenimine-based intravenous delivery of antisense phosphodiester oligodeoxynucleotides to the liver.
Robaczewska M; Guerret S; Remy JS; Chemin I; Offensperger WB; Chevallier M; Behr JP; Podhajska AJ; Blum HE; Trepo C; Cova L
Gene Ther; 2001 Jun; 8(11):874-81. PubMed ID: 11423935
[TBL] [Abstract][Full Text] [Related]
15. In vitro and in vivo reversal of multidrug resistance in a human leukemia-resistant cell line by mdr1 antisense oligodeoxynucleotides.
Cucco C; Calabretta B
Cancer Res; 1996 Oct; 56(19):4332-7. PubMed ID: 8813118
[TBL] [Abstract][Full Text] [Related]
16. [Antisense oligonucleotides: a new therapeutic approach].
Guinot P; Temsamani J
Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
[TBL] [Abstract][Full Text] [Related]
17. Antisense oligonucleotides and prevention of tumor growth: a different approach and proposal for a new method.
Yildiz D; Oztas H; Hilal Ates B
Med Hypotheses; 2005; 64(2):328-32. PubMed ID: 15607566
[TBL] [Abstract][Full Text] [Related]
18. Antisense oligonucleotides as therapeutic agents.
Galderisi U; Cascino A; Giordano A
J Cell Physiol; 1999 Nov; 181(2):251-7. PubMed ID: 10497304
[TBL] [Abstract][Full Text] [Related]
19. Cancer Drug Development: New Targets for Cancer Treatment.
Curt GA
Oncologist; 1996; 1(3):II-III. PubMed ID: 10387987
[TBL] [Abstract][Full Text] [Related]
20. Antisense molecules for targeted cancer therapy.
Wacheck V; Zangemeister-Wittke U
Crit Rev Oncol Hematol; 2006 Jul; 59(1):65-73. PubMed ID: 16750913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]